Comparison of Acceptance and Commitment Therapy and Cognitive Behavior Therapy: Managing Psychological Distress and Its Multifaceted Impact on Stigmatization, Psychological Wellbeing, Social Support and Treatment Adherence in HIV/AIDS Patients (HIV CBT ACT)
研究概览
详细说明
Background & Rationale:
HIV/AIDS is a chronic condition with significant psychological burden. People living with HIV/AIDS experience high levels of depression, anxiety, stress, and stigma, which affect treatment adherence and quality of life. Both Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT) are evidence-based interventions for psychological distress, but their comparative effectiveness in HIV/AIDS patients in Pakistan has not been evaluated. This study aims to compare ACT and CBT for managing psychological distress and improving stigma, wellbeing, social support, and medication adherence.
Objective:
To compare the effectiveness of brief Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT) in reducing psychological distress and improving stigmatization, psychological wellbeing, social support, and medication adherence among HIV/AIDS patients.
Study Design:
Randomized Controlled Trial with single-blind design. Participants will be allocated to three groups using a computer-generated randomization sequence:
- CBT group (n=24): Standard care + 8 weeks of brief CBT
- ACT group (n=24): Standard care + 8 weeks of brief ACT
- Control group (n=24): Standard care only, no specific psychological intervention
A pilot study with 15 participants will be conducted prior to the main trial.
Participants:
- Inclusion: Adults aged 18-40 years with a documented HIV/AIDS diagnosis, receiving ART, actively seeking treatment at Sheikh Zayed Hospital, and providing informed consent.
- Exclusion: Severe cognitive impairment, severe psychiatric conditions requiring specialized care, or prior participation in similar CBT/ACT interventions for HIV/AIDS.
Intervention:
Both ACT and CBT will be delivered as once-weekly sessions of 35-40 minutes for 8 weeks.
- ACT focuses on acceptance, mindfulness, values, committed action, and cognitive diffusion.
- CBT focuses on identifying/challenging negative thoughts, behavioral activation, and coping strategies.
Interventions will be culturally adapted and delivered by therapists with at least a Master's degree and training in CBT/ACT.
Outcome Measures:
Assessments at baseline, post-intervention, and 6-month follow-up using:
- DASS-21: Depression, Anxiety, Stress Scale
- Psychological Well-Being Scale (PWB): 6 domains of wellbeing
- HIV Stigma Scale: To measure perceived stigma
- Multidimensional Perceived Social Support Scale (MPSS): Urdu version
- General Medication Adherence Scale (GMAS): Urdu version
- Mini-Mental State Examination (MMSE): For cognitive screening
Data Collection & Analysis:
Data will be collected using self-report questionnaires. Ethical approval will be obtained from the IRB of Sheikh Zayed Hospital. Informed consent, confidentiality, and voluntary participation will be ensured. Data analysis will compare outcomes across the three groups to evaluate effectiveness.
Ethics:
The study complies with ethical standards for human research. Institutional approval and ongoing informed consent will be maintained. Participant anonymity and data protection will be rigorously enforced.
Duration:
Study duration is not specified in the excerpt, but involves 8-week intervention plus 6-month follow-up.
Institution:
Department of Applied Psychology, The Islamia University Bahawalpur. Principal Investigator: Sadia Batool, Ph.D. Applied Psychology
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Punjab Province
-
Rahim Yar Khan、Punjab Province、巴基斯坦、64200
- Sheikh Zayed Hospital Rahim Yar Khan
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Participants must have a documented medical diagnosis of HIV/AIDS by a healthcare professional.
- Participants should fall within a specified age range, typically from 18 years to 40 years older.
- ACT and CBT treatments will be made available to participants who are receiving ART.
- Participants must be actively receiving or seeking treatment and care for their HIV/AIDS condition at Sheikh Zayed Hospital.
- Individuals must express their voluntary willingness to participate in the study and provide informed consent.
Exclusion Criteria:
- Individuals with severe cognitive impairments that would hinder their ability to engage in assessments or therapy sessions will be excluded.
- Individuals with severe psychiatric conditions that require immediate specialized care beyond the scope of the study will be excluded.
- Individuals with a history of prior participation in a similar cognitive behavior therapy intervention for HIV/AIDS will be excluded to avoid potential confounding effects from previous treatment experiences
学习计划
研究是如何设计的？
设计细节
- 主要用途：支持治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：CBT + Standard Care
|
Participants receive standard ART care plus 8 weekly sessions of brief Cognitive Behavioral Therapy, 35-40 minutes each.
CBT focuses on identifying/challenging negative thoughts, behavioral activation, and coping strategies.
Delivered by Master's-level therapist trained in CBT, culturally adapted for HIV/AIDS patients.
ACT
|
|
实验性的：ACT+ Standard Care
|
Participants receive standard ART care plus 8 weekly sessions of brief Cognitive Behavioral Therapy, 35-40 minutes each.
CBT focuses on identifying/challenging negative thoughts, behavioral activation, and coping strategies.
Delivered by Master's-level therapist trained in CBT, culturally adapted for HIV/AIDS patients.
ACT
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
HIV Stigma Scale
大体时间：Baseline; up to 8 weeks; up to 6 months post-baseline
|
The 40-item HSS scale was first created by Berger et al. in 2001.
Saif and Shehzad (2020) translated and verified it into an Urdu form.
For this investigation, the HSS Urdu version will be utilized.
Four components are evaluated by the HSS: public opinions, disclosure concerns, unfavorable self-image, and individualized stigma.
A 4-point Likert-type scale, ranging from "strongly disagree" to "strongly agree," is used to score each item.
The range of HSS scores is 40 to 160.
Higher scores signify a high level of stigma.
The HSS is a legitimate and trustworthy measure with strong psychometric qualities.
|
Baseline; up to 8 weeks; up to 6 months post-baseline
|
|
The Depression Anxiety Stress Scales (DASS) 21
大体时间：Baseline; up to 8 weeks; up to 6 months post-baseline
|
The Depression Anxiety Stress Scale (DASS) was developed by Dr. Sydney H. Lovibond and Dr. Peter F. Lovibond in 1995 (Lovibond & Lovibond, 1995) as a brief tool to measure the levels of depression, anxiety, and stress in individuals.
The DASS-21 is a shortened version of the original 42-item DASS, with 21 items divided equally among the three scales, allowing for efficient assessment while maintaining accuracy.
Each item is rated on a four-point Likert scale (from "did not apply to me at all" to "applied to me very much"), reflecting the frequency and intensity of negative emotional symptoms over the past week.
The DASS-21 has demonstrated strong reliability, with Cronbach's alpha values typically reported around 0.88 for depression, 0.82 for anxiety, and 0.90 for stress.
This high reliability makes it a widely accepted tool in both clinical and research settings for quickly identifying and differentiating symptoms of depression, anxiety, and stress.
Psychologists utilize the Depressi
|
Baseline; up to 8 weeks; up to 6 months post-baseline
|
|
Psychological well-being scale
大体时间：Baseline; up to 8 weeks; up to 6 months post-baseline
|
The Psychological Well-Being Scale (PWB) was developed by Dr. Carol D. Ryff in 1995 to measure multiple facets of positive functioning and overall psychological well-being (Ryff, 1995).
The 33 components make up the modified SPWB measure.
There are six sub-scales for each of the six positive functioning elements.
The autonomy subscale evaluates a person's feeling of independence and self-determination.
There are five things in it, such as "I tend to be influenced by people with strong opinions."
|
Baseline; up to 8 weeks; up to 6 months post-baseline
|
|
Multidimensional Perceived Social Support Scale (MPSS)
大体时间：Baseline; up to 8 weeks; up to 6 months post-baseline
|
Zimet et al. (1988) created MPSS initially.
Akhtar et al. (2010) translated and verified it into an Urdu version.
The MPSS version that is being used for this investigation is Urdu.
The 12-item, unidimensional MPSS measures an individual's perception of their social support network, which consists of friends, family, and significant others.
A 7-point rating system, ranging from "strongly disagree" to "strongly agree," is used for each issue.
A greater degree of social support is indicated by a higher score.
MPSS has an overall reliability of >0.80, with subscale reliability of 0.82, 0.86, and 0.86, respectively.
|
Baseline; up to 8 weeks; up to 6 months post-baseline
|
|
The Mini-Mental State Examination
大体时间：Baseline; up to 8 weeks; up to 6 months post-baseline
|
The Mini-Mental State Examination (MMSE) is one of the most frequently used and extensively studied concerning precision and accuracy.
MMSE was developed by Folstein M.F., in 1975.
The test can be administered to individuals who are 18-85 years or older.
It is an 11-question measure that tests 5 areas of cognitive function: Orientation, Registration, Attention and Calculation, Recall, and Language.
A score of 23 or less has generally been accepted as indicating the presence of cognitive impairment.
|
Baseline; up to 8 weeks; up to 6 months post-baseline
|
合作者和调查者
赞助
调查人员
- 首席研究员：Dr Arsalan khalid, phd psycholoogy、The islamia university of Bahawalpur
- 首席研究员：Sadia Batool, phd applied psychology、The islamia university of Bahawalpur
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- F22BAPSY4M01006
- 388//IRB/SZMC/SZH (其他赠款/资助编号：Sheikh zayed Medical college hospital. RYK)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.